Oculis OCS 深 沪
等待开盘 11-14 09:30:00 美东时间
7.64
+0.140
+1.87%
华盛通- 最 高7.68
- 今 开7.51
- 成交量 18.40万股
- 最 低 7.28
- 昨 收 7.50
- 总市值 4.73亿
- 52周最高 34.475
- 市盈率 静 --
- 换手率 0.30%
- 52周最低 6.78
- 委 比 -77.91%
- 总股本 6191.96万
- 历史最高 34.475
- 量 比 0.60
- 振 幅 5.33%
- 历史最低 6.26
- 每 手 1
- 风险率 7.90%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
ZUG, Switzerland, Nov. 13, 2026 - Notifications regarding the vesting and settlement of RSUs granted to the Company's directors are attached. The notifications include details for Anthony Rosenberg, Christina Ackermann, Arshad Khanani, and Robert Warner, all dated November 13, 2026.
11-13 21:05
美股大行评级 | 大摩上调AMD目标价至725美元；安进、多邻国绩后获华尔街大行看多
今日重点评级关注：康托·菲茨杰拉德：维持Supernus"超配"评级，目标价从67美元升至87美元；丰业银行：维持Atlas Energy Solutions"跑赢大市"评级，目标价从17美元升至18美元
11-05 14:06
Guggenheim Maintains Buy on Oculis Holding, Lowers Price Target to $40
Guggenheim analyst Yatin Suneja maintains Oculis Holding (NASDAQ:OCS) with a Buy and lowers the price target from $45 to $40.
11-04 22:54
Oculis Appoints Experienced Life Sciences Leader Björn Tackenberg, M.D., Ph.D., as Chief Scientific Officer to Advance Neurology Innovation
Oculis Holding AG has appointed Björn Tackenberg, M.D., Ph.D., as Chief Scientific Officer (CSO) and Aaron Tansy, M.D., as Vice President, Development Franchise Head, Neurology. Tackenberg will lead the company's global scientific strategy and advance Privosegtor, a neuroprotective candidate, through its PIONEER registrational program, exploring its potential in acute MS relapses and other neurological indications. Tansy brings expertise in globa...
11-02 07:00
Oculis to Feature Privosegtor’s Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit
Oculis Holding AG announced positive Phase 2 ACUITY trial results for Privosegtor, a novel neuroprotective candidate for optic neuritis. The trial showed improved visual function, preserved retinal structure, and reduced neurofilament levels. Privosegtor has received Breakthrough Therapy and PRIME designations and is advancing through the PIONEER registrational program. The company will present data at the 6th Asia-Pacific Ophthalmic Innovation S...
10-29 09:39
Oculis to Feature Privosegtor’s Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit
Oculis Holding AG announced positive Phase 2 ACUITY trial results for Privosegtor, a potential first-in-class neuroprotective treatment for optic neuritis. The trial showed improvements in visual function, retinal preservation, and reduced neurofilament levels. Privosegtor has received Breakthrough Therapy and PRIME designations and is advancing in the PIONEER registrational program. Data will be presented at the 6th Asia-Pacific Ophthalmic Innov...
10-29 09:10
美股大行评级 | 潜在涨幅94.37%！摩根士丹利上调西部数据(WDC)目标价至668美元，维持"超配"评级
今日重点评级关注：摩根士丹利：维持西部数据"超配"评级，目标价从643美元升至668美元；摩根大通：维持西部数据"超配"评级，目标价从600美元升至650美元
10-26 12:30
HC Wainwright & Co. Reiterates Buy on Oculis Holding, Maintains $39 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Oculis Holding (NASDAQ:OCS) with a Buy and maintains $39 price target.
10-23 18:32
Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease
Oculis Holding AG announced the completion of randomization in the PREDICT-1 trial for Licaminlimab, a precision medicine targeting TNFR1-mediated dry eye disease (DED). Two-thirds of the 176 enrolled patients carry the TNFR1 genetic variant linked to enhanced response. Licaminlimab aims to address an unmet need for ~1.5 million U.S. patients with moderate-to-severe DED. Topline results are expected by year-end 2026. The trial evaluates efficacy ...
10-19 06:00
Oculis lýkur slembiröðun í PREDICT-1 skráningarrannsókninni á Licaminlimab við TNFR1-miðluðum augnþurrki
<p>Oculis Holding AG has completed enrollment in the PREDICT-1 trial of Licaminlimab, a gene-targeted precision medicine for dry eye disease (DED), with 176 patients, 2/3 of whom have a specific TNFR1 genotype linked to improved clinical response. Licaminlimab aims to address unmet needs in DED treatment by targeting patients with TNFR1-mediated disease, potentially offering the first precision therapy for approximately 1.5 million affected indiv...
10-19 06:00
